Myasthenia Gravis

Latest News

Rystiggo | Image Credit: © UCB
Rozanolixizumab Remains Consistently Safe, Effective for gMG

March 21st 2025

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat anti–acetylcholine receptor– and anti–muscle-specific kinase–positive generalized myasthenia gravis (gMG) in adult patients; administration is subcutaneous and takes approximately 15 minutes.

FDA approval | Image Credit: © Olivier Le Moal-stock.adobe.com
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis

March 15th 2025

Dysphagia | Image Credit: © Zerbor-stock.adobe.com
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction

March 9th 2025

muscarinic acetylcholine receptors | Image Credit: © MohammedElAmine-stock.adobe.com
Disease Burden From Myasthenia Gravis Consistently High

February 26th 2025

Myasthenia gravis | Image Credit: © lhphotos-stock.adobe.com
EU Approves Self-Administered Rozanolixizumab for Myasthenia Gravis

February 24th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo